Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 1.00 |
| ▸ | KDM4A | O75164 | 2/20 | 1.00 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 1.00 |
| ▸ | KDM6B | O15054 | 1/20 | 1.00 |
| ▸ | KDM6A | O15550 | 1/20 | 1.00 |
| ▸ | TET3 | O43151 | 1/20 | 1.00 |
| ▸ | KDM4B | O94953 | 1/20 | 1.00 |
| ▸ | KDM5C | P41229 | 1/20 | 1.00 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 1.00 |
| ▸ | TET2 | Q6N021 | 1/20 | 1.00 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 1.00 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 1.00 |
| ▸ | FTO | Q9C0B1 | 1/20 | 1.00 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 1.00 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 1.00 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 5/20 | 0.75 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.75 |
| ▸ | COMT | P21964 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29349767 | 1.00 | KDM4E (1.00) | KDM4EL3MBTL1KDM4AEGLN1KDM6B | |
| SCHEMBL27468637 | 0.87 | KDM4E (0.77) | KDM4EL3MBTL1KDM4AEGLN1KDM6B | |
| SCHEMBL69673 | 0.87 | KDM4E (0.77) | KDM4EL3MBTL1KDM4AEGLN1KDM6B | |
| SCHEMBL298623 | 0.86 | KDM4E (1.00) | KDM4EL3MBTL1KDM4AEGLN1KDM6B | |
| SCHEMBL11261836 | 0.86 | KDM4E (0.75) | KDM4EL3MBTL1KDM4AEGLN1KDM6B | |
| SCHEMBL7646199 | 0.84 | KDM4E (1.00) | KDM4EL3MBTL1KDM4AEGLN1KDM6B | |
| SCHEMBL29462403 | 0.84 | KDM4E (0.73) | KDM4EL3MBTL1KDM4AEGLN1KDM6B | |
| SCHEMBL163474 | 0.84 | KDM4E (0.73) | KDM4EL3MBTL1KDM4AEGLN1KDM6B | |
| SCHEMBL10582092 | 0.83 | COMT (0.76) | KDM4EL3MBTL1KDM4AEGLN1KDM6B | |
| SCHEMBL28625501 | 0.83 | KDM4E (0.71) | KDM4EL3MBTL1KDM4AEGLN1KDM6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011425-A1 | COMPOSITIONS AND METHODS FOR IMPROVED T CELLS | UNIV TEMPLE (US) | 2025-01-09 | — | — | US | claimed |
| CN-118847623-A | Surface treatment device, surface treatment method of display substrate and display device | 京东方科技集团股份有限公司 | 2024-10-29 | — | — | CN | claimed |
| US-20240245702-A1 | Inhibition of Lysine Demethylase 1 (Lsd1) Induces Differentiation of Hair Cells | MASSACHUSETTS EYE AND EAR INFIRMARY | 2024-07-25 | — | — | US | claimed |
| US-12024715-B2 | Compositions and methods for improved T cells | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-07-02 | — | — | US | claimed |
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | claimed |
| CN-117343127-A | Targeted antitumor prodrug, and preparation method and application thereof | 中国科学技术大学 | 2024-01-05 | — | — | CN | claimed |
| CN-112915087-B | Anti-tumor drug sensitizer based on 5-carboxyl-8-hydroxyquinoline and application thereof | 浙江大学 | 2023-01-24 | — | — | CN | claimed |
| CN-115073446-A | Berberine type alkaloid oxidized pyrazine formic acid quaternary ammonium salt and application thereof in preparing medicines | 中国医学科学院药物研究所 | 2022-09-20 | — | — | CN | claimed |
| US-20220008433-A1 | Inhibition of Lysine Demethylase 1 (Lsd1) Induces Differentiation of Hair Cells | MASSACHUSETTS EYE AND EAR INFIRMARY | 2022-01-13 | — | — | US | claimed |
| WO-2021109796-A1 | ANTI-TUMOR DRUG SENSITIZER EMPLOYING 5-CARBOXY-8-HYDROXYQUINOLINE, AND APPLICATION THEREOF | 浙江大学 | 2021-06-10 | — | — | WO | claimed |
| CN-112915087-A | 5-carboxyl-8-hydroxyquinoline-based antitumor drug sensitizer and application thereof | 浙江大学 | 2021-06-08 | — | — | CN | claimed |
| WO-2020242157-A1 | USE OF IOX1 AS ANTIBIOTIC, ANTI-INFLAMMATORY, AND ANTI-SEPTIC AGENT | 건국대학교 글로컬산학협력단 | 2020-12-03 | — | — | WO | claimed |
| WO-2020112883-A1 | INHIBITION OF LYSINE DEMETHYLASE 1 (LSD1) INDUCES DIFFERENTIATION OF HAIR CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2020-06-04 | — | — | WO | claimed |
| US-10603295-B2 | Sensorineural hair cell differentiation | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2020-03-31 | — | — | US | claimed |
| WO-2017187287-A1 | MEDIUM FOR BIOPRESERVATION OF CELLS AND OTHER BIOLOGICAL MATERIALS AT CRYOGENIC AND HYPOTHERMIC CONDITIONS AND USES THEREOF | SMITH & NEPHEW, INC. (US) | 2017-11-02 | — | — | WO | claimed |
| US-20170042842-A1 | Sensorineural Hair Cell Differentiation | MASSACHUSETTS EYE AND EAR INFIRMARY | 2017-02-16 | — | — | US | claimed |
| WO-2015168149-A2 | SENSORINEURAL HAIR CELL DIFFERENTIATION | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2015-11-05 | — | — | WO | claimed |
| CN-103301884-B | Preparation method and application of modified active carbon fiber based on 8-hydroxyquinoline ferrum | UNIV ZHEJIANG SCIENCE & TECH | 2014-09-24 | — | — | CN | claimed |
| CN-103301884-A | Preparation method and application of modified active carbon fiber based on 8-hydroxyquinoline ferrum | UNIV ZHEJIANG SCIENCE & TECH | 2013-09-18 | — | — | CN | claimed |
| EP-4691479-A2 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | Janssen Biotech, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4194548-B1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | JANSSEN BIOTECH INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12427128-B2 | Sensorineural hair cell differentiation | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-09-30 | — | — | US | disclosed |
| CN-120501875-A | Composition for realizing dual benefits of treatment and immunological memory and application thereof | 沈阳药科大学 | 2025-08-19 | — | — | CN | disclosed |
| US-12378201-B2 | Histone demethylase inhibitors for treating cancers | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-08-05 | — | — | US | disclosed |
| CN-119286847-A | Nano magnetic bead with adjustable surface potential and preparation method and application thereof | 南方科技大学 | 2025-01-10 | — | — | CN | disclosed |
| US-20250011425-A1 | COMPOSITIONS AND METHODS FOR IMPROVED T CELLS | UNIV TEMPLE (US) | 2025-01-09 | — | — | US | disclosed |
| CN-118847623-A | Surface treatment device, surface treatment method of display substrate and display device | 京东方科技集团股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20240271185-A1 | METHODS AND COMPOSITIONS FOR IDENTIFYING METHYLATED CYTOSINES | ILLUMINA, INC. | 2024-08-15 | — | — | US | disclosed |
| CN-118436649-A | Application of small molecule inhibitor IOX1 in preparation of drugs for treating atrial fibrillation | 南京鼓楼医院 | 2024-08-06 | — | — | CN | disclosed |
| US-20240245702-A1 | Inhibition of Lysine Demethylase 1 (Lsd1) Induces Differentiation of Hair Cells | MASSACHUSETTS EYE AND EAR INFIRMARY | 2024-07-25 | — | — | US | disclosed |
| US-12024715-B2 | Compositions and methods for improved T cells | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-07-02 | — | — | US | disclosed |
| CN-114007671-B | Methods and compositions for treating chronic inflammatory lesions, metaplasias, dysplasias, and cancers of epithelial tissue | 休斯敦大学体系 | 2024-06-14 | — | — | CN | disclosed |
| WO-2024081789-A2 | HISTONE DEMETHYLASE INHIBITORS FOR TREATING CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-18 | — | — | WO | disclosed |
| CN-117881795-A | Methods and compositions for identifying methylated cytosines | 因美纳有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117343127-A | Targeted antitumor prodrug, and preparation method and application thereof | 中国科学技术大学 | 2024-01-05 | — | — | CN | disclosed |
| US-20230265432-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOID LEUKEMIA | Sanford Burnham Prebys Medical Discovery Institute | 2023-08-24 | — | — | US | disclosed |
| CN-116376858-A | Application of monoamine oxidase from microorganism as catalyst in preparation of quinoline or quinoline derivative | 浙江大学杭州国际科创中心 | 2023-07-04 | — | — | CN | disclosed |
| EP-4194548-A1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | Janssen Biotech, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2023097995-A1 | APPLICATION OF COMPOUND IN SOLAR CELL | 西安隆基乐叶光伏科技有限公司 | 2023-06-08 | — | — | WO | disclosed |
| WO-2023097995-A1 | APPLICATION OF COMPOUND IN SOLAR CELL | 西安隆基乐叶光伏科技有限公司 | 2023-06-08 | — | — | WO | disclosed |
| CN-116144650-A | Method for detecting content and/or activity of FTO and subfamily thereof | 东南大学 | 2023-05-23 | — | — | CN | disclosed |
| CN-112915087-B | Anti-tumor drug sensitizer based on 5-carboxyl-8-hydroxyquinoline and application thereof | 浙江大学 | 2023-01-24 | — | — | CN | disclosed |
| CN-112915087-B | Anti-tumor drug sensitizer based on 5-carboxyl-8-hydroxyquinoline and application thereof | 浙江大学 | 2023-01-24 | — | — | CN | disclosed |
| CN-112915087-B | Anti-tumor drug sensitizer based on 5-carboxyl-8-hydroxyquinoline and application thereof | 浙江大学 | 2023-01-24 | — | — | CN | disclosed |
| EP-3472303-B1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | JANSSEN BIOTECH INC (US) | 2022-12-14 | — | — | EP | disclosed |
| CN-115372323-A | Method for detecting enzymatic activity of DNA 5mC or RNA m6A methylase/demethylase | 中国科学院上海药物研究所 | 2022-11-22 | — | — | CN | disclosed |
| US-RE49240-E1 | Inhibitors of histone deacetylase | THE GENERAL HOSPITAL CORPORATION (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220306584-A1 | HISTONE DEMETHYLASE INHIBITORS FOR TREATING CANCERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2022-09-29 | — | — | US | disclosed |
| CN-115073446-A | Berberine type alkaloid oxidized pyrazine formic acid quaternary ammonium salt and application thereof in preparing medicines | 中国医学科学院药物研究所 | 2022-09-20 | — | — | CN | disclosed |
| US-20220218638-A1 | Sensorineural Hair Cell Differentiation | MASSACHUSETTS EYE AND EAR INFIRMARY | 2022-07-14 | — | — | US | disclosed |
| US-20220202792-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2022-06-30 | — | — | US | disclosed |
| US-20220206003-A1 | BIOMARKERS FOR PREDICTING RESISTANCE TO CANCER DRUGS | INSTITUT CURIE (FR) | 2022-06-30 | — | — | US | disclosed |
| WO-2022121236-A1 | CD47 EXPRESSION INHIBITOR AND USE THEREOF IN COMBINATION WITH IMMUNOTHERAPEUTIC DRUG | 浙江大学 | 2022-06-16 | — | — | WO | disclosed |
| US-11298328-B2 | Sensorineural hair cell differentiation | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2022-04-12 | — | — | US | disclosed |
| CN-114335346-A | Application of compound in solar cell | 西安隆基乐叶光伏科技有限公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3962559-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | University of Houston System (US) | 2022-03-09 | — | — | EP | disclosed |
| EP-3959521-A1 | BIOMARKERS FOR PREDICTING RESISTANCE TO CANCER DRUGS | Institut Curie (FR) | 2022-03-02 | — | — | EP | disclosed |
| CN-114007671-A | Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancer of epithelial tissue | 休斯敦大学体系 | 2022-02-01 | — | — | CN | disclosed |
| US-20220008433-A1 | Inhibition of Lysine Demethylase 1 (Lsd1) Induces Differentiation of Hair Cells | MASSACHUSETTS EYE AND EAR INFIRMARY | 2022-01-13 | — | — | US | disclosed |
| US-20210310022-A1 | MASSIVELY PARALLEL COMBINATORIAL GENETICS FOR CRISPR | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-10-07 | — | — | US | disclosed |
| EP-3847889-A1 | BIOCIDAL COMPOSITIONS COMPRISING IRON CHELATORS | Arch Chemicals, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210198669-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING MUSCULAR DISORDERS AND DYSTROPHIES, STEROID SIDE EFFECTS, AND INFLAMMATION | CHILDREN'S NATIONAL MEDICAL CENTER (US) | 2021-07-01 | — | — | US | disclosed |
| WO-2021109796-A1 | ANTI-TUMOR DRUG SENSITIZER EMPLOYING 5-CARBOXY-8-HYDROXYQUINOLINE, AND APPLICATION THEREOF | 浙江大学 | 2021-06-10 | — | — | WO | disclosed |
| WO-2021109796-A1 | ANTI-TUMOR DRUG SENSITIZER EMPLOYING 5-CARBOXY-8-HYDROXYQUINOLINE, AND APPLICATION THEREOF | 浙江大学 | 2021-06-10 | — | — | WO | disclosed |
| WO-2021109796-A1 | ANTI-TUMOR DRUG SENSITIZER EMPLOYING 5-CARBOXY-8-HYDROXYQUINOLINE, AND APPLICATION THEREOF | 浙江大学 | 2021-06-10 | — | — | WO | disclosed |
| CN-112915087-A | 5-carboxyl-8-hydroxyquinoline-based antitumor drug sensitizer and application thereof | 浙江大学 | 2021-06-08 | — | — | CN | disclosed |
| CN-112915087-A | 5-carboxyl-8-hydroxyquinoline-based antitumor drug sensitizer and application thereof | 浙江大学 | 2021-06-08 | — | — | CN | disclosed |
| CN-107429246-B | Massively parallel combinatorial genetics for CRISPR | 麻省理工学院 | 2021-06-01 | — | — | CN | disclosed |
| CN-112516141-A | Inhibitors of CD47 expression and their use in combination with immunotherapeutic agents | 浙江大学 | 2021-03-19 | — | — | CN | disclosed |
| US-20210069230-A1 | SYNERGISTIC DRUG COMBINATIONS PREDICTED FROM GENOMIC FEATURES AND SINGLE-AGENT RESPONSE PROFILES | THE BROAD INSTITUTE, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2020257733-A1 | HISTONE DEMETHYLASE INHIBITORS FOR TREATING CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020242157-A1 | USE OF IOX1 AS ANTIBIOTIC, ANTI-INFLAMMATORY, AND ANTI-SEPTIC AGENT | 건국대학교 글로컬산학협력단 | 2020-12-03 | — | — | WO | disclosed |
| WO-2020242157-A1 | USE OF IOX1 AS ANTIBIOTIC, ANTI-INFLAMMATORY, AND ANTI-SEPTIC AGENT | 건국대학교 글로컬산학협력단 | 2020-12-03 | — | — | WO | disclosed |
| WO-2020219963-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020216898-A1 | BIOMARKERS FOR PREDICTING RESISTANCE TO CANCER DRUGS | INSTITUT CURIE (FR) | 2020-10-29 | — | — | WO | disclosed |
| US-20200338030-A1 | Sensorineural Hair Cell Differentiation | MASSACHUSETTS EYE AND EAR INFIRMARY | 2020-10-29 | — | — | US | disclosed |
| EP-3708155-A1 | MASSIVELY PARALLEL COMBINATORIAL GENETICS FOR CRISPR | Massachusetts Institute Of Technology (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20200270573-A1 | COMPOSITIONS AND METHODS FOR IMPROVED T CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-08-27 | — | — | US | disclosed |
| US-20200208116-A1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | JANSSEN BIOTECH, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| US-20200181284-A1 | EPIGENETIC INHIBITORS FOR SENSITIZING HEMATOLOGIC OR OTHER MALIGNANCIES TO GLUCOCORTICOID THERAPY | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2020-06-11 | — | — | US | disclosed |
| WO-2020112883-A1 | INHIBITION OF LYSINE DEMETHYLASE 1 (LSD1) INDUCES DIFFERENTIATION OF HAIR CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2020-06-04 | — | — | WO | disclosed |
| US-20200170249-A1 | Biocidal Compositions Comprising Iron Chelators | ARCH CHEMICALS, INC. | 2020-06-04 | — | — | US | disclosed |
| US-10633635-B2 | Methods for production of functional beta cells | JANSSEN BIOTECH, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| EP-3212789-B1 | MASSIVELY PARALLEL COMBINATORIAL GENETICS FOR CRISPR | MASSACHUSETTS INST TECHNOLOGY (US) | 2020-04-22 | — | — | EP | disclosed |
| US-10603295-B2 | Sensorineural hair cell differentiation | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2020-03-31 | — | — | US | disclosed |
| WO-2019200224-A1 | SYNERGISTIC DRUG COMBINATIONS PREDICTED FROM GENOMIC FEATURES AND SINGLE-AGENT RESPONSE PROFILES | THE BROAD INSTITUTE, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| US-10433548-B2 | Biocidal compositions comprising iron chelators | ARCH CHEMICALS, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| EP-3204509-B1 | BIOLUMINESCENT SUCCINATE DETECTION ASSAY | PROMEGA CORP (US) | 2019-07-10 | — | — | EP | disclosed |
| US-20190133985-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | Orbus Therapeutics, Inc. | 2019-05-09 | — | — | US | disclosed |
| CN-109721535-A | For detecting small-molecule fluorescent probe, the preparation method and applications of matrix metalloproteinase | 重庆医科大学 | 2019-05-07 | — | — | CN | disclosed |
| US-20190100769-A1 | MASSIVELY PARALLEL COMBINATORIAL GENETICS FOR CRISPR | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-04-04 | — | — | US | disclosed |
| US-9988343-B2 | Inhibitors of histone deacetylase | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20180042905-A1 | METHODS OF TREATING HEPATITIS B VIRUS | GILEAD SCIENCES, INC. | 2018-02-15 | — | — | US | disclosed |
| US-20180042905-A1 | METHODS OF TREATING HEPATITIS B VIRUS | GILEAD SCIENCES, INC. | 2018-02-15 | — | — | US | disclosed |
| US-20170362572-A1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | JANSSEN BIOTECH, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362572-A1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | JANSSEN BIOTECH, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| WO-2017194958-A1 | ASSAY | SCHOFIELD CHRISTOPHER J (GB) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017194958-A1 | ASSAY | SCHOFIELD CHRISTOPHER J (GB) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017187287-A1 | MEDIUM FOR BIOPRESERVATION OF CELLS AND OTHER BIOLOGICAL MATERIALS AT CRYOGENIC AND HYPOTHERMIC CONDITIONS AND USES THEREOF | SMITH & NEPHEW, INC. (US) | 2017-11-02 | — | — | WO | disclosed |
| EP-3212789-A2 | MASSIVELY PARALLEL COMBINATORIAL GENETICS FOR CRISPR | Massachusetts Institute of Technology (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-3204509-A1 | BIOLUMINESCENT SUCCINATE DETECTION ASSAY | Promega Corporation (US) | 2017-08-16 | — | — | EP | disclosed |
| US-9677117-B2 | Bioluminescent succinate detection assay | PROMEGA CORPORATION (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170042842-A1 | Sensorineural Hair Cell Differentiation | MASSACHUSETTS EYE AND EAR INFIRMARY | 2017-02-16 | — | — | US | disclosed |
| US-20160303095-A1 | METHODS OF TREATING HEPATITIS B VIRUS | GILEAD SCIENCES, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160303095-A1 | METHODS OF TREATING HEPATITIS B VIRUS | GILEAD SCIENCES, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160272579-A1 | INHIBITORS OF HISTONE DEACETYLASE | DANA-FARBER CANCER INSTITUTE, INC. | 2016-09-22 | — | — | US | disclosed |
| WO-2016070037-A2 | MASSIVELY PARALLEL COMBINATORIAL GENETICS FOR CRISPR | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016057084-A1 | BIOLUMINESCENT SUCCINATE DETECTION ASSAY | PROMEGA CORPORATION (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160102338-A1 | BIOLUMINESCENT SUCCINATE DETECTION ASSAY | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2016-04-14 | — | — | US | disclosed |
| WO-2015168149-A2 | SENSORINEURAL HAIR CELL DIFFERENTIATION | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2015-11-05 | — | — | WO | disclosed |
| EP-2906038-A1 | BIOCIDAL COMPOSITIONS COMPRISING IRON CHELATORS | Arch Chemicals, Inc. (US) | 2015-08-19 | — | — | EP | disclosed |
| US-8871789-B2 | Method of preventing or treating viral infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871789-B2 | Method of preventing or treating viral infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-10-28 | — | — | US | disclosed |
| CN-103301884-B | Preparation method and application of modified active carbon fiber based on 8-hydroxyquinoline ferrum | UNIV ZHEJIANG SCIENCE & TECH | 2014-09-24 | — | — | CN | disclosed |
| US-20140154189-A1 | Biocidal Compositions Comprising Iron Chelators | ARCH CHEMICALS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| CN-103301884-A | Preparation method and application of modified active carbon fiber based on 8-hydroxyquinoline ferrum | UNIV ZHEJIANG SCIENCE & TECH | 2013-09-18 | — | — | CN | disclosed |
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2013-05-16 | — | — | US | disclosed |
| US-7030063-B1 | Cyclohexenonquinolinoyl-derivatives as herbicidal agents | BASF AKTIENGESELLSCHAFT (DE) | 2006-04-18 | — | — | US | disclosed |
| EP-1112256-B1 | CYCLOHEXENONQUINOLINOYL-DERIVATIVES AS HERBICIDAL AGENTS | BASF AG (DE) | 2003-10-29 | — | — | EP | disclosed |
| CN-1077891-C | 5-phenyl-3- (piperidin-4-yl) -1,3, 4-oxadiazol-2 (3H) -one derivatives useful as 5-HT4 or H3 receptor ligands | SYNTHELABO (FR) | 2002-01-16 | — | — | CN | disclosed |
| EP-1112256-A1 | CYCLOHEXENONQUINOLINOYL-DERIVATIVES AS HERBICIDAL AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000014069-A1 | CYCLOHEXENONQUINOLINOYL-DERIVATIVES AS HERBICIDAL AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-16 | — | — | WO | disclosed |
| CN-1239962-A | 1,4-diazabicyclo [2,2,2] oct-2-ylmethyl derivatives, their preparation and therapeutic application | SYNTHELABO (FR) | 1999-12-29 | — | — | CN | disclosed |
| CN-1202169-A | 5-phenyl-3- (piperidin-4-yl) -1, 3, 4-oxadiazol-2 (3H) -one derivatives useful as 5-HT 4 or H3 receptor ligands | SYNTHELABO (FR) | 1998-12-16 | — | — | CN | disclosed |
| US-4738796-A | HEAT STABILIZATION USING MIXTURE OF 8-HYDROXYQUINOLINE AND ORGANIC PHOSPHATES | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1988-04-19 | — | — | US | disclosed |
| US-4738796-A | HEAT STABILIZATION USING MIXTURE OF 8-HYDROXYQUINOLINE AND ORGANIC PHOSPHATES | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1988-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181284-A1 | EPIGENETIC INHIBITORS FOR SENSITIZING HEMATOLOGIC OR OTHER MALIGNANCIES TO GLUCOCORTICOID THERAPY | NR3C1, EZH2, MECP2 | KDM4E 92/4885L3MBTL1 919/4885KDM4A 124/4885 |
| US-20210198669-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING MUSCULAR DISORDERS AND DYSTROPHIES, STEROID SIDE EFFECTS, AND INFLAMMATION | TNNC1, MYOF, MBNL1 | KDM4E 3883/4885L3MBTL1 1587/4885KDM4A 4215/4885 |
| US-20170362572-A1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | SLC2A3, SLC2A2, SLC2A1 | KDM4E 3567/4885L3MBTL1 3892/4885KDM4A 2411/4885 |
| US-12378201-B2 | Histone demethylase inhibitors for treating cancers | KDM4A, KDM1B, KDM4B | KDM4E 6/4885L3MBTL1 1038/4885KDM4A 1/4885 |
| US-10633635-B2 | Methods for production of functional beta cells | SLC2A3, SLC2A1, SLC2A2 | KDM4E 2905/4885L3MBTL1 4006/4885KDM4A 1515/4885 |
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | KDM1B, KDM1A, KDM2A | KDM4E 21/4885L3MBTL1 274/4885KDM4A 9/4885 |
| US-20160272579-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC3 | KDM4E 92/4885L3MBTL1 2155/4885KDM4A 114/4885 |
| US-20220008433-A1 | Inhibition of Lysine Demethylase 1 (Lsd1) Induces Differentiation of Hair Cells | KDM7A, KDM1B, KDM1A | KDM4E 19/4885L3MBTL1 638/4885KDM4A 10/4885 |
| US-20180042905-A1 | METHODS OF TREATING HEPATITIS B VIRUS | KDM1B, KDM5B, KDM5A | KDM4E 25/4885L3MBTL1 2096/4885KDM4A 10/4885 |
| US-10433548-B2 | Biocidal compositions comprising iron chelators | SLC40A1, TFRC, SLC39A14 | KDM4E 3199/4885L3MBTL1 2179/4885KDM4A 3068/4885 |
| US-20220306584-A1 | HISTONE DEMETHYLASE INHIBITORS FOR TREATING CANCERS | KDM4A, KDM1B, KDM4B | KDM4E 6/4885L3MBTL1 1038/4885KDM4A 1/4885 |
| US-20140154189-A1 | Biocidal Compositions Comprising Iron Chelators | SLC40A1, TFRC, SLC39A14 | KDM4E 3199/4885L3MBTL1 2179/4885KDM4A 3068/4885 |
| US-20240245702-A1 | Inhibition of Lysine Demethylase 1 (Lsd1) Induces Differentiation of Hair Cells | KDM7A, KDM1B, KDM1A | KDM4E 19/4885L3MBTL1 638/4885KDM4A 10/4885 |
| US-20200170249-A1 | Biocidal Compositions Comprising Iron Chelators | SLC40A1, TFRC, SLC39A14 | KDM4E 3199/4885L3MBTL1 2179/4885KDM4A 3068/4885 |
| US-20160303095-A1 | METHODS OF TREATING HEPATITIS B VIRUS | KDM1B, KDM5B, KDM5A | KDM4E 25/4885L3MBTL1 2096/4885KDM4A 10/4885 |
| US-20220202792-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | FABP2, MUC1, FABP6 | KDM4E 4709/4885L3MBTL1 3774/4885KDM4A 4018/4885 |
| US-20200208116-A1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | SLC2A3, SLC2A2, SLC2A1 | KDM4E 3567/4885L3MBTL1 3892/4885KDM4A 2411/4885 |
| US-20190133985-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | AHCY, SRM, MAT2A | KDM4E 930/4885L3MBTL1 3736/4885KDM4A 970/4885 |
| US-20210069230-A1 | SYNERGISTIC DRUG COMBINATIONS PREDICTED FROM GENOMIC FEATURES AND SINGLE-AGENT RESPONSE PROFILES | ABCC1, TSG101, BRCA1 | KDM4E 3762/4885L3MBTL1 2176/4885KDM4A 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.